GNH USA

Europe — EMA

Nebivolol Tarbis

GNH USA supplies Nebivolol Tarbis (Nebivolol), a beta blocker for hypertension and heart failure.

Nebivolol

Request sourcing

1
Pack/s

What is Nebivolol?

Nebivolol, the active ingredient in Nebivolol Tarbis, is a beta blocker presented as an oral formulation for oral use. It is used to lower elevated blood pressure and improve cardiovascular outcomes in adults.

GNH USA supplies Nebivolol Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, manufactures under EU GMP guidelines, and provides reliable global distribution.

What is Nebivolol used for?

Nebivolol is indicated for conditions involving elevated blood pressure and related cardiovascular disorders.

Hypertension: reduces systolic and diastolic blood pressure by decreasing heart rate and promoting vasodilation. Heart failure (reduced ejection fraction): improves cardiac output and lowers hospitalization risk in chronic heart‑failure patients. Ischemic heart disease: enhances endothelial function and may alleviate angina symptoms.

What are the side effects of Nebivolol?

Nebivolol may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache - Fatigue - Dizziness - Nausea - Bradycardia - Nasal congestion

Serious or Rare Side Effects: - Severe bradycardia - Symptomatic hypotension - Heart block - Bronchospasm - Allergic reactions (rash, swelling, anaphylaxis) - Hepatic injury

What precautions apply to Nebivolol?

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

Blood pressure monitoring: check baseline and periodic readings. Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction. Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension. Diabetes mellitus: monitor blood glucose as beta‑blockade may mask hypoglycemia symptoms. Renal impairment: dose adjustment may be required in severe renal dysfunction. Hepatic impairment: use cautiously in patients with significant liver disease. Store at ambient temperature: keep in original container, protect from moisture and light.

What does Nebivolol interact with?

Nebivolol can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increased risk of heart block. - Clonidine withdrawal: may cause severe hypertension. - MAO inhibitors: potential hypertensive crisis. - Antiarrhythmic agents (e.g., amiodarone): heightened bradycardia.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Diuretics: can enhance hypotensive response. - ACE inhibitors or ARBs: may increase risk of excessive blood pressure lowering. - Antidiabetic drugs: beta‑blockade may mask hypoglycemia signs. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise nebivolol plasma levels.

Frequently asked questions

What is Nebivolol Tarbis used for?+
Nebivolol Tarbis contains nebivolol, a selective β1‑adrenergic blocker indicated for the treatment of hypertension and, in some jurisdictions, for chronic heart failure with reduced ejection fraction. It helps lower blood pressure and improve cardiovascular outcomes when prescribed by a qualified healthcare professional.
How does nebivolol work?+
Nebivolol selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility, while simultaneously stimulating endothelial nitric‑oxide synthase. The increased nitric‑oxide release causes vasodilation of peripheral vessels, which together lower systemic vascular resistance and arterial blood pressure.
What is the usual dose of nebivolol?+
The appropriate dose of Nebivolol Tarbis is determined individually by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical condition. Dosage adjustments may be required for special populations, and patients should follow the prescriber’s instructions precisely.
Is nebivolol safe during pregnancy or breastfeeding?+
Safety data for nebivolol in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.
How do I order Nebivolol Tarbis from GNH USA?+
To request Nebivolol Tarbis, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does nebivolol compare with other beta‑blockers?+
Compared with older non‑selective beta‑blockers, nebivolol offers β1‑selectivity and additional nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability. It is often preferred when clinicians seek a beta‑blocker that also improves endothelial function, though individual response varies.
How should Nebivolol Tarbis be stored?+
Nebivolol Tarbis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.
How is Nebivolol Tarbis administered?+
Nebivolol Tarbis is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and avoid crushing or chewing unless specifically instructed.
What are the most serious risks associated with nebivolol?+
The most serious adverse events include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare cases of hepatic injury or allergic reactions. Patients should seek immediate medical attention if they experience fainting, chest pain, difficulty breathing, or signs of an allergic response.
Who should not use nebivolol?+
Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled severe asthma. Caution is also advised for individuals with significant hepatic impairment or those taking medications listed under major interactions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nebivolol
Route
Oral Use
Manufacturer
Tarbis Farma, S.L.
Origin
EU

Related products

Nebivolol 20 mg/1

Nebivolol 20 mg/1

Nebivolol · 20 mg

nebivolol
TABLET
Major Pharmaceuticals
USA
NEBIVOLOL 2.5 mg/1

NEBIVOLOL 2.5 mg/1

Nebivolol · 2.5 mg

Nebivolol
TABLET
Major Pharmaceuticals
USA
NEBIVOLOL 5 mg/1

NEBIVOLOL 5 mg/1

Nebivolol · 5 mg

Nebivolol
TABLET
Major Pharmaceuticals
USA
NEBIVOLOL 10 mg/1

NEBIVOLOL 10 mg/1

Nebivolol · 10 mg

Nebivolol
TABLET
Major Pharmaceuticals
USA